Cereno Scientific’s drug candidate CS1 has obtained strengthened patent protection through its third patent family
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s third patent family has obtained issued patents in Australia and South Korea. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“This is the fourth announcement in a short period of time that is related to the expansion of patent protection for assets in our portfolio. I am pleased to see the progress we are making with our intellectual property rights (IPR) as